Antibody as carrier of 131I in cancer diagnosis and treatment
Antibody as carrier of 131I in cancer diagnosis and treatment
复制标题
抗体作为131I载体在癌症诊断和治疗中的应用
作者：
Mbbs T. GHOSE;MD A. GUCLU;MSc J. TAI;MD A. S. MACDONALD;MD S. T. NORVELL;MD J. AQUINO;Mbbs T. Chose;M. Mammen;P. Seaman;R. Sekaran;B. Stevenson
针对小鼠EL4淋巴瘤、埃利希腹水癌和几种人类恶性肿瘤的细胞表面定位异源抗体可以与不同量的131 I结合，而不干扰这些抗体与其各自肿瘤细胞的反应性。将小鼠肿瘤细胞体外暴露于放射性碘标记的抗肿瘤抗体，或将放射性碘标记的抗肿瘤抗体注射到预先接种肿瘤细胞的小鼠中，根据抗体携带的131 I活性的量，导致部分或完全肿瘤抑制。单独注射相当量的免疫球蛋白或与正常球蛋白结合的131 I均未引起任何肿瘤抑制。发现腹膜内注射放射性碘标记的抗EL4抗体优先定位于EL4淋巴瘤的皮下移植物中。在两名癌症患者的转移瘤中观察到静脉注射的放射性碘化抗体的类似定位。
Cell‐surface localizing heterologous antibodies against mouse EL4 lymphoma, Ehrlich ascites carcinoma, and several human malignant tumors could be bound to varying amounts of131I without interfering with the reactivity of these antibodies with their respective tumor cells. Exposure of the mouse tumor cells to radio‐iodinated antitumor antibodies in vitro, or the injection of radioiodinated antitumor antibodies into mice preinoculated with tumor cells resulted in either partial or complete tumor inhibition depending upon the amount of 131I activity carried by the antibodies. Injecten of comparable amounts of the immunoglobulin alone or of 131I bound to normal globulin did not cause any tumor inhibition. Intraperitoneally injected radio‐iodinated anti‐EL4 antibody was found to localize preferentially in the subcutaneous transplants of EL4 lymphoma. Similar localization of intravenously injected radio‐iodinated antibodies was observed in the metastases of two cancer patients.